April 24, 2019 | Michael Easterling and Samantha Bonar
City of Hope’s bone marrow transplant program recently performed the procedure on its 15,000th patient, a remarkable milestone considering that the initiative started with just two physicians, three beds and guarded expectations in 1976.
City of Hope to participate in NCI-MATCH clinical trial
April 5, 2019 | City of Hope
City of Hope’s Clinical Molecular Diagnostic Laboratory (CMDL) is participating as a CLIA-Certified/Accredited laboratory in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) precision medicine trial.
New Study: Deploying Genetic Screens Early May Offer Some Benefits
February 7, 2017 | Jyoti Madhusoodanan
Next-generation sequencing (NGS) tests can quickly pinpoint tumor mutations that can be targeted with specific drugs, offering a route to precision therapies for many cancer types. Coupled with new drugs that target tumor-specific genomic changes, NGS tests carry the potential to transform modern cancer care.
NCI-MATCH Trial focuses on mutations for rare cancers, not tumor site
April 15, 2015 | Nicole Levine
Precision medicine is becoming a reality for cancers with genetic mutations that are practically household names, such as those behind some breast cancers and lung cancers. A new multicenter trial focuses on providing precision treatments for rare cancers based on genetics, not tumor site.